Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

## 中國寶沙發展控股有限公司 China Bozza Development Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1069)

## VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION AGREEMENT

This announcement is made by China Bozza Development Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business development of the Group.

Reference is made to the announcement of the Company dated 4 August 2023 in relation to the strategic cooperation between the Company and Shenzhen Jiashisen Investment Group Company Limited\* (深圳 佳仕森投資(集團)有限公司) ("Shenzhen Jiashisen") for the development of ginseng business (the "Announcement"). Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless otherwise defined.

The Board is pleased to announce that the management of the Company and Shenzhen Jiashisen had a meeting after the entering into of the Strategic Cooperation Agreement to further discuss the details of the development of the Business. During the meeting, the Company further enquired the capability of Shenzhen Jiashisen in the American Ginseng market so as to substantiate the cooperation plan. Shenzhen Jiashisen specialises in the plantation, research and development, processing and sales of American ginseng in Shaanxi province. It possesses the entire production line for the development of American Ginseng and has extensive network with a number of universities for the research and development of American Ginseng.

During the meeting, the management of the Company and Shenzhen Jiashisen discussed the type and grading of the ginseng to be developed, the plantation and processing method and the expected timetable for the development of the Business. The parties intend to mutually build up a brand for the American ginseng to be produced under the Business and intend to commence trial run for the Business in the last quarter of 2023. During the trial run, the parties will set up a production line. The quality of the American ginseng will be tested regularly at certified laboratories, and the production line will be fine-tuned as and when appropriate to ensure that the grading of the American ginseng produced is up to standard. The tests conducted will mainly focus on the level of active ingredients in the American ginseng especially ginsenosides, essential oil, trace elements and polysaccharide. Once the production line is fully developed which can produce stable quality and quantity of American ginseng for consumption, the parties may also consider to develop other health products and by-products with American ginseng, such as Chinese herbal drinks, ginseng wine, skincare products and cosmetic products.

The Company will further discuss the distribution of work and manpower and the sales target with Shenzhen Jiashisen and will keep shareholders and potential investors of the Company informed of any material update.

Shareholders and potential investors of the Company are reminded that the matters contemplated under the Strategic Cooperation Agreement are still subject to the entering into of definitive agreements, and may or may not materialise as described or at all. Upon entering into definitive agreements under the Strategic Cooperation Agreement, further announcement(s) will be made by the Company as and when appropriate in accordance with the Listing Rules. Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By Order of the Board China Bozza Development Holdings Limited Professor Fei Phillip Chairman and Executive Director

\* For identification purpose only

Hong Kong, 10 August 2023

As at the date of this announcement, the Board comprises Professor Fei Phillip, Mr. Li Wenjun, Ms. Hui Hing Conniel, Mr. Lai Chi Yin Samuel and Mr. Wang Yibin as the executive Directors; and Mr. Gu Sotong as the non-executive Director; and Mr. Liu Zhaoxiang, Ms. Wong Hoi Ying, Mr. Guo Zhonglong and Mr. Chan Wai Lung as the independent non-executive Directors.